The FDA warns of a fake Desport vaccine and the union criticizes the procedure

The National Agency for Medicines and Healthcare products warned occupational health professionals on November 13, 2026 of the discovery of a counterfeit pharmaceutical product at the border, namely a Desport serum designed to prepare a solution for injection with a concentration of 500 units of A-type botulinum toxin.

The agency explained that Epson's British informant, who has a greenhouse marketing license, confirmed that it was not manufactured for that batch. The tests showed that the product's source was unknown and that the fast response code on its packaging contained abnormal markings, prompting the agency to call on professionals to exclusively supply legal and approved distribution channels and be cautious when discharging and using it.

The Pharmacists' Union criticized the need to simply call on professionals to be vigilant, stressing that priority should be focused on law enforcement and taking strict action against those involved in counterfeit drug trafficking. The syndicate questioned the role of pharmaceutical auditing in monitoring the practices of healthcare interferees and tracking distribution channels.

The syndicate stressed that Desport's medicine falls within the category of deposit medicines which are supplied exclusively through the central pharmacy and delivered to the patient through the pharmacy only to ensure traceability and pharmaceutical accountability. The union demanded to identify the source of the product and its access routes and refer suspicious files to the police or prosecutor's office instead of saving on the alert.